Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 10.9% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares dropped 10.9% during mid-day trading on Wednesday . The stock traded as low as GBX 271.50 ($3.42) and last traded at GBX 281 ($3.54). Approximately 83,679 shares changed hands during trading, an increase of 589% from the average daily volume of 12,139 shares. The stock had previously closed at GBX 315.50 ($3.97).

Hemogenyx Pharmaceuticals Stock Performance

The stock has a market cap of £10.02 million, a price-to-earnings ratio of -1,437.47 and a beta of 3.14. The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The stock’s 50-day moving average is GBX 359.05 and its 200-day moving average is GBX 126.40.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.